Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Value-Based Cancer Care

- PMLiVE

Word Monster and the PM Society join forces to elevate medical writing standards

Both partners aim to improve training and foster innovation in the medical communications industry

- PMLiVE

Free Live Webinar – Uniting Communities for Rare Disease Clinical Trial Success

Join this live webinar focusing on patient recruitment and retention in rare disease trials.

Innovative Trials

- PMLiVE

Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

- PMLiVE

Tiziana shares promising results for intranasal foralumab in multiple sclerosis

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

New immune cell discovery could lead to personalised breast cancer treatments

The study revealed the key features of immune cells in helping the body’s immune system fight cancer

- PMLiVE

Supercharged strategies: it’s time for pharma to get brave and bold

The importance of putting boldness front and centre

- PMLiVE

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains...

Impetus Digital

- PMLiVE

TRANSFORMING CME IMPACT: MEDSCAPE’S GAME-CHANGING APPROACH

It’s time for the CME industry to evolve. During recent years, access to data, modern technologies, and methodologies have allowed for deeper analysis of data and a better understanding of...

Medscape Education Global

- PMLiVE

Novartis and PeptiDream expand peptide discovery collaboration in deal worth over $2.8bn

The agreement builds on the companies’ peptide-drug conjugate collaboration announced in 2019

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study

More than two million cases of breast cancer were diagnosed globally in 2022

- PMLiVE

UK study reveals significantly higher risk of second cancers among breast cancer survivors

Breast cancer is currently the most commonly diagnosed cancer in the UK, affecting around 56,000 people annually

- PMLiVE

Data integration and the AI healthcare revolution

Looking at some of the chief opportunities and challenges for digital health providers in implementing and scaling technological solutions in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links